• Biomarker discovery advances with new platform integration

Analysers

Biomarker discovery advances with new platform integration

Mar 18 2024

Synexa Life Sciences, a global Clinical Laboratory Services provider for the biopharma industry, has announced the integration of the Olink® Target immunoassays and the Olink® Signature Q100 instrument into its extensive suite of biomarker discovery platforms.

The incorporation of Olink Signature Q100 marks a significant advancement in Synexa's commitment to delivering leading biomarker and bioanalytical solutions to its biotech and pharma clientele. The Olink Signature Q100 system facilitates the processing and analysis of Olink Target assays in disease-focused panel formats, requiring as little as 1 μL of serum, plasma, or other biological sample types. Through the profiling of protein biomarkers, deeper insights into disease mechanisms are unveiled, aiding in the identification of potential therapeutic targets and expediting the development of innovative treatments.

Justin Devine, Chief Innovation Officer, remarked: "By integrating the Olink platform into our service offerings, Synexa can further bolster researchers’ endeavours in translational research, patient-centric sampling, and extracellular vesicle analysis."

Emile Lens, CEO at Synexa Life Sciences, emphasised: "The incorporation of Olink into the Synexa technology portfolio underscores our ongoing commitment to enhancing our biomarker and bioanalysis capabilities across various expertise areas, including oncology, immuno-oncology, infectious diseases, and more. The inclusion of Olink in our service portfolio enables us to address clinical research inquiries more effectively, significantly broadening access to proteomics for deeper biological insights among our global clientele."

The Olink Signature Q100 is purpose-built to meet the precise requirements of clinical laboratory services in the biotech, pharmaceutical,and contract research organisation (CRO) sectors. Offering a wide range of capabilities, including high-throughput multiplex protein biomarker measurement and data analysis, the system employs a seamless workflow, saving time at the lab bench. This enables researchers to process large samples and datasets efficiently, accelerating drug discovery and enhancing personalised medicine initiatives.

More information online


Digital Edition

Lab Asia 31.2 April 2024

April 2024

In This Edition Chromatography Articles - Approaches to troubleshooting an SPE method for the analysis of oligonucleotides (pt i) - High-precision liquid flow processes demand full fluidic c...

View all digital editions

Events

Analiza

May 28 2024 Tel Aviv, Israel

HTC-18

May 28 2024 Leuven, Belgium

PREP 2024

May 28 2024 Philadelphia, PA, USA

CISILE 2024

May 29 2024 Beijing, China

ASMS Conference

Jun 02 2024 Anaheim, CA, USA

View all events